125404-04-8 Usage
Description
TCN 238 is an allosteric modulator of the mGlu4 receptor, which is a type of receptor found in the brain. It has the potential to be useful in the treatment of motor dysfunction and Parkinson's disease due to its ability to modulate the activity of the mGlu4 receptor. Additionally, TCN 238 is orally bioavailable, which means it can be taken by mouth and is absorbed into the body.
Uses
Used in Pharmaceutical Industry:
TCN 238 is used as a therapeutic agent for the treatment of motor dysfunction. It modulates the activity of the mGlu4 receptor, which is involved in the regulation of motor function, and may help improve motor function in individuals with motor dysfunction.
TCN 238 is also used as a therapeutic agent for the treatment of Parkinson's disease. It may help alleviate the motor symptoms associated with the disease by modulating the activity of the mGlu4 receptor.
In addition to its use in the treatment of motor dysfunction and Parkinson's disease, TCN 238's oral bioavailability makes it a promising candidate for further research and development in the pharmaceutical industry for other potential applications.
Check Digit Verification of cas no
The CAS Registry Mumber 125404-04-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,5,4,0 and 4 respectively; the second part has 2 digits, 0 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 125404-04:
(8*1)+(7*2)+(6*5)+(5*4)+(4*0)+(3*4)+(2*0)+(1*4)=88
88 % 10 = 8
So 125404-04-8 is a valid CAS Registry Number.
125404-04-8Relevant articles and documents
An orally bioavailable positive allosteric modulator of the mGlu 4 receptor with efficacy in an animal model of motor dysfunction
East, Stephen P.,Bamford, Samantha,Dietz, Matthias G.A.,Eickmeier, Christian,Flegg, Adam,Ferger, Boris,Gemkow, Mark J.,Heilker, Ralf,Hengerer, Bastian,Kotey, Adrian,Loke, Pui,Schaenzle, Gerhard,Schubert, Hans-Dieter,Scott, John,Whittaker, Mark,Williams, Mildred,Zawadzki, Przemyslaw,Gerlach, Kai
, p. 4901 - 4905 (2010)
A high-throughput screening campaign identified 4-((E)-styryl)-pyrimidin-2- ylamine (11) as a positive allosteric modulator of the metabotropic glutamate (mGlu) receptor subtype 4. An evaluation of the structure-activity relationships (SAR) of 11 is described and the efficacy of this compound in a haloperidol-induced catalepsy rat model following oral administration is presented.
